15.79
+1.22%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Yarrow Bioscience
From its filings with the US Securities and Exchange Commission
Yarrow Bioscience is based in New Haven, Connecticut and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker YARW. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $570,000 and a net loss of $26.5m. At that date it held total assets of $30.2m and shareholders' equity of $27.8m.
We are a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat inflammatory and immune-mediated conditions with high unmet need.
We have exclusive worldwide rights to research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (“BET”) inhibitors for the treatment of any disease, disorder or condition in humans, which we licensed from Tay Therapeutics Ltd., formerly known as In4Derm Ltd ("Tay"). BET proteins are epigenetic enablers of transcription that regulate the expression of specific genes. Each BET protein consists of two bromodomains (“BD1” and “BD2”) and one end terminal (“ET”) domain. Through our transaction with Tay, we obtained access to a library of new small molecule BET inhibitor compounds including those that inhibit both BD1 and BD2 (“pan-BD” BET inhibitor) and that selectively inhibit BD2 (“BD2-selective” BET inhibitor). We initially focused our development efforts with these molecules on immune-mediated inflammatory diseases, which are not being targeted by current BET inhibitors in development.
Quoted from its 10-K, filed 27 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Listed since
- 25 Jan 2018
- Employees
- 10
- Website
- yarrowbioscience.com ↗
- Head office
- 470 JAMES STREET, SUITE 007, NEW HAVEN, CT, 06513
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- YB-101 targets TSHR for Graves' disease treatment in clinical stage.
- New York headquarters supports biotech innovation and talent access.
- 10 employees focus on developing transformative autoimmune therapies.
Weaknesses
- Incorporated in 2025, limited operational history for a clinical-stage company.
- 10 employees may restrict research and development capacity.
- Clinical-stage status indicates early development phase with high risk.
Opportunities
- Graves' disease and thyroid eye disease market offers unmet therapeutic needs.
- Monoclonal antibody therapies are growing in the biotech sector.
- New York biotech ecosystem provides potential partnerships and funding.
Threats
- Graves' disease treatment competition from established biotech firms.
- Clinical-stage development faces regulatory approval challenges.
- Thyroid eye disease market requires significant investment for treatment.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.